Hodgkin Lymphoma
ctDNA MRD Monitoring with Strong Prognostic Value; Molecular Profiling Identifies Checkpoint Inhibitor Sensitivity
Clinical Overview
Classical Hodgkin lymphoma (cHL) is characterized by sparse malignant Hodgkin-Reed-Sternberg (HRS) cells comprising only 0.1-10% of the tumor mass, embedded within extensive reactive inflammatory infiltrates. This unique biology creates technical challenges for ctDNA detection but yields powerful prognostic information when successful.
ctDNA testing serves two distinct clinical roles in Hodgkin lymphoma: MRD monitoring after treatment and molecular profiling for genotype-directed therapy selection. MRD detection demonstrates 92-97% baseline sensitivity and provides exceptional prognostic stratification, with hazard ratios ranging from 6.9 to 8.7 depending on timepoint. The HD21 trial substudy demonstrated that MRD-positive patients after 2 cycles of therapy have 6.9-fold higher risk of progression compared to MRD-negative patients (4-year PFS: 72.2% vs 95.3%, p < 0.0001).
Beyond MRD, molecular profiling reveals near-universal 9p24.1 amplification (100% of cases) affecting PD-L1, PD-L2, and JAK2, creating sensitivity to checkpoint inhibitors with 69-72% objective response rates. JAK/STAT pathway mutations occur in over 90% of cases, and genomic subtyping identifies two major subtypes (H1: 68%, H2: 32%) with distinct biological characteristics.
Why ctDNA Matters in Hodgkin Lymphoma
- MRD prognostic power: HR 6.9 after 2 cycles (HD21 trial substudy: 4-year PFS 95.3% MRD- vs 72.2% MRD+)
- High sensitivity: 92-97% baseline detection; 93.8% using targeted sequencing approaches
- Molecular clearance precedes imaging: Earlier detection than PET-CT
- 9p24.1 amplification: 100% of cases; enables checkpoint inhibitor therapy (nivolumab, pembrolizumab: 69-72% ORR)
- JAK/STAT alterations: >90% prevalence; ruxolitinib + nivolumab achieves 53% ORR
- Genomic subtypes: H1 (68%) vs H2 (32%) with distinct characteristics
ctDNA Testing Methodology
Clinical Context: ctDNA testing in Hodgkin lymphoma employs tumor-informed approaches using baseline samples to identify patient-specific mutations, then tracking those mutations at subsequent timepoints for MRD monitoring or molecular profiling.
Tumor-Informed Approach
Definition: Uses a baseline sample (tissue biopsy or baseline blood draw) to identify the patient's specific mutations, then tracks those identified mutations at MRD monitoring timepoints.
Workflow:
- Step 1 - Baseline profiling: Sequence baseline sample (tissue or blood) to identify patient's mutations
- Step 2 - MRD tracking: Test blood at post-treatment timepoints for those identified mutations
- Key advantage: Knowing which mutations to track dramatically improves sensitivity
Clinical Application in Hodgkin Lymphoma:
- Baseline sensitivity: 92-97% detection rate
- Enables tracking of sparse HRS cell-derived ctDNA
- Identifies patient-specific immunoglobulin gene rearrangements or somatic mutations
Important Note: Tumor-informed testing can use fixed gene panels; it does not require custom-designed assays. The key distinction is that baseline profiling identifies which mutations to monitor, rather than testing "blind" at MRD timepoints.
LIQOMICS Testing Solutions for Hodgkin Lymphoma
LymphoVista offers tumor-informed ctDNA testing for Hodgkin Lymphoma using either baseline tissue or baseline plasma samples for mutation profiling, followed by longitudinal MRD monitoring.
Key Features:
- Works with baseline tissue biopsy or baseline blood draw for initial profiling
- Tracks patient-specific mutations for high-sensitivity MRD detection
- Serial monitoring optimized for lymphoma biology
- Non-invasive blood-based surveillance
- Comprehensive genotyping and mutational profiling
MRD Detection: Clinical Utility
Detection Performance
Clinical Context: Despite low HRS cell content (0.1-10%), modern ctDNA approaches achieve high baseline detection rates through tumor-informed tracking strategies.
Baseline Detection Performance:
- Overall sensitivity: 92-97% at diagnosis
- Targeted sequencing approach: 93.8% detection using CAPP-seq methodology
- Detection challenge: Low tumor cellularity requires highly sensitive methods
- Technical consideration: Clonal hematopoiesis (CHIP) interferes in 33% of cases
Reference: Spina V et al. Blood 2018;131:2413-2425
Prognostic Value: HD21 Trial MRD Substudy
Clinical Context: The HD21 trial MRD substudy using the LymphoVista HL assay demonstrated that ctDNA MRD status after 2 cycles of chemotherapy powerfully predicts treatment outcomes in advanced-stage classical Hodgkin lymphoma.
HD21 MRD Substudy Results (72 patients):
- Patient population: Advanced-stage cHL patients treated in GHSG HD21 trial (BrECADD vs eBEACOPP)
- MRD assessment timepoint: After 2 cycles of chemotherapy (MRD-2)
- MRD-negative patients (81.5%): 4-year PFS 95.3%
- MRD-positive patients (18.5%): 4-year PFS 72.2%
- Hazard Ratio: HR 6.9 (95% CI 4.5-10.6, p < 0.0001)
- Clinical significance: MRD status provides powerful risk stratification independent of treatment arm
- Subgroup findings: MRD-2 remained prognostic in both BrECADD (HR 25.4) and eBEACOPP (HR 2.8) arms
Interpretation: The HD21 substudy demonstrates that ultrasensitive ctDNA MRD assessment after 2 cycles identifies patients at significantly higher relapse risk, supporting consideration of treatment intensification in MRD-positive patients.
Reference: Mattlener J, Ferdinandus J, Schneider J, et al. Blood 2024;144(Supplement 1):4355
Hazard Ratios by Timepoint
Clinical Context: The prognostic value of MRD status varies by assessment timepoint, with validated data from the HD21 substudy demonstrating strong prognostic power after 2 cycles of therapy.
| Assessment Timepoint | Hazard Ratio (HR) | Clinical Interpretation | Study |
|---|---|---|---|
| After 2 cycles (MRD-2) | HR 6.9 (95% CI 4.5-10.6) | Early MRD persistence predicts treatment failure; 4-year PFS 72.2% (MRD+) vs 95.3% (MRD-) | HD21 substudy (Mattlener 2024) |
| End of treatment | HR 8.7 | EOT MRD+ strongly associated with relapse | Spina et al. 2018 |
Clinical Application: The HD21 substudy provides Level 1 evidence that MRD assessment after 2 cycles of chemotherapy identifies patients at higher relapse risk, supporting risk-adapted treatment strategies.
Lead Time Advantage
Clinical Context: ctDNA MRD clearance occurs earlier than radiographic resolution, providing advance warning of treatment response or resistance.
Molecular vs Radiographic Response:
- ctDNA clearance: Precedes PET-CT normalization by weeks to months
- Persistent ctDNA: Detects residual disease before radiographic progression
- Clinical utility: Earlier identification of inadequate response may enable treatment modification
- Current limitation: Interventional benefit not yet proven (PRECISE-HL trial ongoing)
Clinical Recommendation: MRD Monitoring
Current Evidence Level: Prognostic biomarker with exceptional risk stratification (HR up to 13.2)
Potential Applications:
- MRD-negative: May support treatment de-escalation to reduce late toxicities (e.g., bleomycin omission)
- MRD-positive (especially if PET-negative): Consider treatment intensification, autologous stem cell transplant, or novel therapy enrollment
Important Limitation: ctDNA-guided therapy adaptation not yet validated in randomized trials. The PRECISE-HL study is evaluating whether MRD-directed treatment changes improve outcomes. Current use should focus on risk stratification and clinical trial enrollment rather than routine therapy de-escalation.
Genotyping: Clinical Utility
Clinical Context: Molecular profiling of Hodgkin lymphoma reveals near-universal genomic alterations that predict sensitivity to specific targeted therapies, particularly checkpoint inhibitors and JAK inhibitors.
9p24.1 Amplification: PD-L1/PD-L2/JAK2
Clinical Context: The 9p24.1 chromosomal region contains PD-L1, PD-L2, and JAK2 genes. Amplification of this region is a defining molecular feature of classical Hodgkin lymphoma, occurring in 100% of cases and creating exquisite sensitivity to checkpoint blockade.
9p24.1 Amplification Profile:
- Prevalence: 100% of classical HL cases
- Affected genes: PD-L1 (CD274), PD-L2 (PDCD1LG2), JAK2
- Mechanism: Copy number gain leads to PD-L1/PD-L2 overexpression on HRS cells
- Biological consequence: Immune evasion through PD-1/PD-L1 axis activation
- Therapeutic implication: Strong rationale for PD-1 blockade
Checkpoint Inhibitor Therapy
Evidence: PD-1 inhibitors demonstrate exceptional activity in relapsed/refractory Hodgkin lymphoma driven by near-universal 9p24.1 amplification.
| Agent | Objective Response Rate | Complete Response Rate | Clinical Context |
|---|---|---|---|
| Nivolumab (monotherapy) | 69% | 16% | Relapsed/refractory after ASCT |
| Pembrolizumab (monotherapy) | 72% | 28% | Relapsed/refractory after brentuximab |
| Nivolumab + brentuximab vedotin | 85% | 67% | Combination shows synergistic activity |
Clinical Interpretation: The 100% prevalence of 9p24.1 amplification explains the consistently high response rates to checkpoint inhibitors across all Hodgkin lymphoma patients, unlike solid tumors where PD-L1 expression is heterogeneous.
References: Ansell SM et al. N Engl J Med 2015;372:311-319; Chen R et al. J Clin Oncol 2017;35:2125-2132
JAK/STAT Pathway Mutations
Clinical Context: Beyond 9p24.1 amplification, over 90% of Hodgkin lymphoma cases harbor mutations activating the JAK/STAT signaling pathway, creating additional therapeutic vulnerability.
JAK/STAT Alterations:
- Prevalence: >90% of classical HL cases
- Common mutations: STAT6, JAK2, SOCS1 alterations
- Pathway activation: Drives proliferation and survival of HRS cells
- Therapeutic target: JAK inhibitors (ruxolitinib)
JAK Inhibitor Combination Therapy
Evidence: Combining JAK inhibition with checkpoint blockade demonstrates clinical activity in heavily pretreated patients.
Ruxolitinib + Nivolumab Combination:
- Objective response rate: 53%
- Patient population: Relapsed/refractory after checkpoint inhibitor monotherapy
- Rationale: Dual targeting of PD-1 and JAK/STAT pathways
- Current status: Investigational; clinical trials ongoing
Reference: Ramchandren R et al. Blood 2019;134:2497-2506
Genomic Subtypes: H1 vs H2
Clinical Context: Molecular profiling identifies two distinct genomic subtypes of classical Hodgkin lymphoma with different mutational landscapes and biological characteristics.
| Subtype | Prevalence | Molecular Features | Clinical Characteristics |
|---|---|---|---|
| H1 subtype | 68% | STAT6 mutations, B-cell signature enrichment | May have distinct response patterns |
| H2 subtype | 32% | Alternative mutational profile, different pathway activation | Biological and potentially therapeutic differences |
Clinical Utility: Subtype classification is primarily of research interest currently, but may inform future treatment selection strategies as subtype-specific therapies emerge.
Brentuximab Vedotin: CD30-Directed Therapy
Clinical Context: While not typically assessed via ctDNA testing, CD30 (a cell surface marker) is near-universally expressed on HRS cells and represents a major therapeutic target. CD30 expression is assessed via immunohistochemistry rather than molecular profiling.
Brentuximab Vedotin Efficacy:
- Monotherapy ORR: 75% in relapsed/refractory disease
- Combination with AVD (frontline): Superior outcomes vs ABVD chemotherapy
- Combination with nivolumab: 85% ORR, 67% CR (synergistic with checkpoint blockade)
- Post-ASCT consolidation: Reduces relapse risk by 57% (HR 0.43)
Reference: Connors JM et al. N Engl J Med 2018;378:331-344
Clinical Recommendation: Genotype-Directed Therapy
9p24.1 Amplification (100% of cases):
- First-line checkpoint inhibitor indication: Consider pembrolizumab or nivolumab in relapsed/refractory setting
- Expected efficacy: 69-72% ORR as monotherapy
- Combination approach: Nivolumab + brentuximab achieves 85% ORR
JAK/STAT Pathway Activation (>90% of cases):
- Investigational approach: Ruxolitinib + checkpoint inhibitor combinations
- Current efficacy: 53% ORR in checkpoint-refractory patients
- Clinical trial consideration: For patients progressing on checkpoint monotherapy
Note: Unlike solid tumors, biomarker testing is less critical in Hodgkin lymphoma given near-universal 9p24.1 amplification. All relapsed/refractory patients are candidates for checkpoint inhibitors regardless of specific molecular profiling.
Clinical Summary
ctDNA testing in Hodgkin lymphoma demonstrates exceptional prognostic value for MRD monitoring (HR 6.9 in HD21 substudy) and reveals near-universal therapeutic targets, particularly 9p24.1 amplification enabling checkpoint inhibitor therapy. However, interventional validation remains incomplete.
Evidence-Based Recommendations
MRD Monitoring (Strong Prognostic Value):
- Baseline detection: 92-97% sensitivity; 93.8% with targeted sequencing
- Prognostic stratification: HR 6.9 after 2 cycles (HD21 substudy), 8.7 at end of treatment
- HD21 substudy finding: MRD-positive patients after 2 cycles have 6.9-fold higher progression risk; 4-year PFS 72.2% (MRD+) vs 95.3% (MRD-)
- Lead time advantage: Molecular clearance precedes radiographic response
- Current limitation: Prognostic but not yet predictive; interventional benefit unproven
- Clinical use: Risk stratification, clinical trial enrollment, consideration of treatment intensification
Molecular Profiling (Actionable Targets):
- 9p24.1 amplification (100%): PD-L1/PD-L2/JAK2 copy number gain
- Nivolumab: 69% ORR
- Pembrolizumab: 72% ORR
- Nivolumab + brentuximab: 85% ORR, 67% CR
- JAK/STAT mutations (>90%): Pathway activation
- Ruxolitinib + nivolumab: 53% ORR in checkpoint-refractory patients
- Genomic subtypes: H1 (68%) vs H2 (32%) with distinct molecular features
- CD30 expression: Near-universal; brentuximab vedotin achieves 62-85% ORR depending on combination
Key Limitations:
- CHIP interference: 33% of patients show clonal hematopoiesis requiring careful interpretation
- De-escalation not validated: ctDNA-guided therapy reduction unproven (PRECISE-HL trial ongoing)
- Prognostic not predictive: MRD identifies risk but interventional benefit uncertain
- Technical requirements: Highly sensitive methods needed due to low HRS cell content
Bottom Line: ctDNA testing in Hodgkin lymphoma provides exceptional prognostic information (HR 6.9 for MRD-positive patients after 2 cycles in HD21 substudy; 4-year PFS 72.2% vs 95.3%) and reveals universal therapeutic targets (9p24.1 amplification enabling 69-72% ORR with checkpoint inhibitors). However, ctDNA-guided treatment adaptation remains investigational pending completion of interventional trials. Current applications focus on risk stratification, treatment intensification in high-risk patients, and clinical trial enrollment rather than routine therapy de-escalation.
References
- Spina V, Bruscaggin A, Cuccaro A, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 2018;131:2413-2425.
- Mattlener J, Ferdinandus J, Schneider J, et al. Lymphovista HL - a Validated Assay for Genotyping and MRD Assessment in Hodgkin Lymphoma. Blood 2024;144(Supplement 1):4355.
- Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin lymphoma. N Engl J Med 2015;372:311-319.
- Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35:2125-2132.
- Ramchandren R, Domingo-Domenech E, Rueda A, et al. Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study. J Clin Oncol 2019;37:1997-2007.
- Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma. N Engl J Med 2018;378:331-344.
Evidence summary as of January 2026 | Document Version: 2.0